Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid.

European journal of cancer (Oxford, England : 1990) - 1 Apr 2017

Tahara Makoto, Schlumberger Martin, Elisei Rossella, Habra Mouhammed Amir, Kiyota Naomi, Paschke Ralf, Dutcus Corina E, Hihara Taro, McGrath Shannon, Matijevic Mark, Kadowaki Tadashi, Funahashi Yasuhiro, Sherman Steven I

Abstract excerpt

BACKGROUND: Lenvatinib significantly prolonged progression-free survival (PFS) versus placebo in the phase III Study of (E7080) LEnvatinib in differentiated Cancer of the Thyroid (SELECT) of patients with radioiodine-refractory differentiated thyroid cancer. This exploratory analysis investigated potential predictive biomarkers of lenvatinib efficacy and target engagement. PATIENTS AND METHODS: Circulating...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiopoietin-2
Share to Double-Blind Method

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fibroblast Growth Factor-23

Share to Fibroblast Growth Factors

Share to GTP Phosphohydrolases

Share to Phenylurea Compounds

Share to Quinolines

Share to Receptors, Fibroblast Growth Factor

Source

Identifiers

PMID: 28237867
DOI: 10.1016/j.ejca.2017.01.013

Genes

FGF23
BRAF
HRAS
KRAS
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid.PMID 28237867Read ↗

Evolving molecularly targeted therapies for advanced-stage thyroid cancers.Semantic proximity Read ↗

Differentiated thyroid cancers: a comprehensive review of novel targeted therapies.Semantic proximity Read ↗

Expression of angiogenic switch, cachexia and inflammation factors at the crossroad in undifferentiated thyroid carcinoma with BRAF(V600E).Semantic proximity Read ↗

Targeted therapy in thyroid cancer: molecular alterations and clinical management.Semantic proximity Read ↗

Characterization of Advanced RAS-driven Follicular-derived Thyroid Cancers and Review of Future Therapeutic Avenues.Semantic proximity Read ↗

A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers.Semantic proximity Read ↗

Thyroid cancer in 2010: a roadmap for targeted therapies.Semantic proximity Read ↗

Lenvatinib Plus Anti-PD-1 Combination Therapy for Advanced Cancers: Defining Mechanisms of Resistance in an Inducible Transgenic Model of Thyroid CancerSemantic proximity Read ↗

Real-world outcomes and prognostic factors in anaplastic thyroid cancer: evidence from the REGETNE-Thyroid cohort.Semantic proximity Read ↗

Evaluating new treatments for anaplastic thyroid cancer.Semantic proximity Read ↗

Integrative Bioinformatics Approach to Identify Prognostic Gene Signatures for Risk Stratification in Thyroid CarcinomaSemantic proximity Read ↗

New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.